Skip to main content
Journal cover image

Evidence strength in FDA premarket approval of cardiovascular devices.

Publication ,  Journal Article
Kong, DF; Hasselblad, V; Krucoff, MW
Published in: JAMA
April 28, 2010

Duke Scholars

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

April 28, 2010

Volume

303

Issue

16

Start / End Page

1599 / 1600

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Uncertainty
  • Risk
  • Randomized Controlled Trials as Topic
  • General & Internal Medicine
  • Equipment and Supplies
  • Device Approval
  • Cardiovascular Diseases
  • 42 Health sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kong, D. F., Hasselblad, V., & Krucoff, M. W. (2010). Evidence strength in FDA premarket approval of cardiovascular devices. JAMA, 303(16), 1599–1600. https://doi.org/10.1001/jama.2010.511
Kong, David F., Vic Hasselblad, and Mitchell W. Krucoff. “Evidence strength in FDA premarket approval of cardiovascular devices.JAMA 303, no. 16 (April 28, 2010): 1599–1600. https://doi.org/10.1001/jama.2010.511.
Kong DF, Hasselblad V, Krucoff MW. Evidence strength in FDA premarket approval of cardiovascular devices. JAMA. 2010 Apr 28;303(16):1599–600.
Kong, David F., et al. “Evidence strength in FDA premarket approval of cardiovascular devices.JAMA, vol. 303, no. 16, Apr. 2010, pp. 1599–600. Pubmed, doi:10.1001/jama.2010.511.
Kong DF, Hasselblad V, Krucoff MW. Evidence strength in FDA premarket approval of cardiovascular devices. JAMA. 2010 Apr 28;303(16):1599–1600.
Journal cover image

Published In

JAMA

DOI

EISSN

1538-3598

Publication Date

April 28, 2010

Volume

303

Issue

16

Start / End Page

1599 / 1600

Location

United States

Related Subject Headings

  • United States Food and Drug Administration
  • United States
  • Uncertainty
  • Risk
  • Randomized Controlled Trials as Topic
  • General & Internal Medicine
  • Equipment and Supplies
  • Device Approval
  • Cardiovascular Diseases
  • 42 Health sciences